BI-4464

Target: This ligand targets polo-like kinase 1 (PLK1) in biochemical or cellular target-engagement studies.

Mechanism of Action: Used as the target-protein recognition element, this ligand provides the binding interface for polo-like kinase 1 (PLK1). In PROTAC design, a derivatizable position on the ligand can be connected through an optimized linker to an E3 ligase ligand, such as a CRBN, VHL, or IAP recruiter, while preserving productive target engagement. The resulting bifunctional molecule brings polo-like kinase 1 (PLK1) into proximity with the recruited E3 ligase, enabling ternary-complex formation. If the complex has favorable geometry and residence time, target lysine ubiquitination is promoted, leading to proteasome-dependent degradation in experimental systems.

• PROTAC-Mediated Target Degradation: BI-4464 can be used as a ligand component in PROTAC constructs to drive proximity between an E3 ligase and a chosen target protein. This enables ubiquitination and subsequent proteasomal degradation, allowing researchers to interrogate loss-of-function phenotypes and validate degradation mechanisms in cellular and biochemical systems.

• E3 Ligase Recruitment Optimization: BI-4464-derived PROTAC designs can be optimized by varying linker length, attachment position, and E3 ligase choice to tune ternary complex formation. Researchers can assess how these parameters influence ubiquitin transfer efficiency, degradation kinetics, and selectivity, using immunoblotting, proteomics, and live-cell degradation assays.

• Mechanistic Studies of Ubiquitination: Incorporating BI-4464 into PROTACs supports mechanistic experiments that dissect ubiquitination pathways. By monitoring target polyubiquitin chain formation, proteasome dependence, and degradation intermediates, researchers can determine whether BI-4464-based constructs promote productive ubiquitination and how they respond to pathway perturbations.

• Proteome-Wide Selectivity Profiling: BI-4464-based PROTACs can be applied to evaluate degradation selectivity across the proteome. Combining targeted degradation readouts with global proteomics helps identify off-target degradations, pathway-level effects, and compensatory responses, informing rational redesign of ligand engagement and PROTAC architecture.

Structure: The structure of BI-4464 is characterized by primary or secondary amine/basic nitrogen centers; amide/urea/sulfonamide hydrogen-bonding motifs; halogenated aryl/heteroaryl ring system; heteroaromatic protein-recognition scaffold. These features provide defined hydrogen-bonding, hydrophobic, and steric elements that can support affinity retention while enabling analogue-based linker-vector selection.

Reactivity: The amine/basic nitrogen-containing motif can be evaluated for acylation, sulfonylation, alkylation, or carbamate/urea linker installation when that vector is solvent exposed. For PROTAC construction, the POI ligand can be paired with CRBN ligands such as thalidomide, pomalidomide, or lenalidomide analogues, VHL ligands such as VH032 derivatives, or less common IAP/MDM2/cIAP-recruiting ligands, with alkyl, PEG, piperazine, triazole, or amide linkers screened for ternary-complex formation. In practice, incorporation into PROTACs should begin from derivatives that preserve the reported binding pharmacophore, followed by systematic variation of linker length, polarity, rigidity, and exit-vector geometry to optimize target engagement, E3 recruitment, and cellular degradation readouts.